FLT3 and acute myeloid leukemia: Specifically targeting FLT3-mutated AML patient cells with FLT3-specific CAR-T-cells should carry a low risk for FLT3 antigen loss as the mutated FLT3 represents an AML ‘driver mutation’ [80].